REVERSAL AGENTS IN NONVALVULAR ATRIAL FIBRILLATION PATIENTS HOSPITALIZED FOR BLEEDING: A REAL-WORLD ANALYSIS  by Robinson, Scott et al.
A419
JACC April 1, 2014
Volume 63, Issue 12
Arrhythmias and Clinical EP
rEVErsaL agEnts in nonVaLVuLar atriaL fibriLLation patiEnts hospitaLizEd for bLEEding: a 
rEaL-worLd anaLysis
Poster Contributions
Hall C
Sunday, March 30, 2014, 3:45 p.m.-4:30 p.m.
Session Title: Arrhythmias and Clinical EP: New Observations Affecting Clinical Management
Abstract Category: 4. Arrhythmias and Clinical EP: AF/SVT
Presentation Number: 1217-106
Authors: Scott Robinson, Bruce D. Bowdy, Yonghua Jing, Robyn Schaiff, Veronica Lee, Ellen McMahon, Bernadette H. Johnson, Daniel Wiederkehr, 
Premier Healthcare Solutions, Charlotte, NC, USA
objectives: To describe the use of reversal therapies in non-valvular atrial fibrillation (NVAF) patients admitted with a bleed prior to hospitalization
methods:  The Premier research database was queried to identify adult NVAF patients discharged between July 2008 and June 2012 who were 
bleeding on admission. Bleeding was identified using ICD-9 diagnosis codes. The resultant patient population was linked to data of the Optum 
Clinformatics Data Mart to determine which drugs and type of care were provided in the 90 days prior to hospitalization. Rates of Vitamin K use 
among patients taking warfarin prior to hospitalization were calculated.
results:  There were 1,837 patients, average age of 77.2 (SD 10.2), which met the selection. Prior to hospitalization, 37.8% received warfarin, 
36.1% received anticoagulants only, 7.3% received antiplatelet only, and 3.6% received both anticoagulant and antiplatelet. The majority (71.1%) 
were diagnosed with gastrointestinal bleeds (GI), while 14.1% were diagnosed with intracranial bleeds. Finally, 28.1% utilized Vitamin K and 42.1% 
utilized a blood product.
conclusions:  Management of bleeding in NVAF patients vary across types of bleed and also the anticoagulant therapies utilized prior to 
hospitalization. Despite the availability of Vitamin K, only 52.6% of patients using warfarin with GI bleeds received Vitamin K during hospitalization. 
Similarly, 53.8% of patients using warfarin with intracranial hemorrhage received Vitamin K during hospitalization.
Break down of reversal agents by bleed type and drug utilization prior to hospitalization
Bleed Type Drugs Used up to 90 days Prior to Hospitalization
Treatment during 
hospitalization
All patients GI^ Bleed** IC^^ Bleed**
Any Warfarin 
exposure
Only 
antiplatelet 
exposure
Only anticoagulant 
exposure
No anticoagulant/ 
antiplatelet 
exposure
1,837 1,307 259 695 135 663 972
Any Vitamin K 516 (28.1%) 369 (28.2%) 71 (27.4%) 372(53.5%) 9(6.7%) 336(50.7%) 132(13.6%)
Any Blood product 774(42.1%) 592(45.3%) 89(34.4%) 408(58.7%) 41(30.4%) 383(57.8%) 310(31.9%)
Vitamin K Alone*** 145(7.9%) 104(8.0%) 18(6.9%) 103(14.8%) 4(3.0%) 92(13.9%) 38(3.9%)
Blood product alone*** 400(21.8%) 324(24.8%) 36(13.9%) 139(20.0%) 35(25.9%) 139(21.0%) 214(22.0%)
Vitamin K and blood 
product***
368(20.0%) 265(20.3%) 50(19.3%) 267(38.4%) 5(3.7%) 242(36.5%) 93(9.6%)
Other*** (not in above 
groups)
924(50.3%) 614(47.0%) 155(59.8%) 186(26.8%) 91(67.4%) 190(28.7%) 627(64.5%)
*Not mutually exclusive 
categories
**based 
upon ICD-9 
CM discharge 
diagnosis code
***Mutually 
exclusive 
categories
^GI - Gastrointestinal
^^IC - 
Intracranial
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